Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages

  Maur, Michela ^a   Tomasello, Chiara ^a   Frassoldati, Antonio ^b   Dieci, Maria Vittoria ^a   Barbieri, Elena ^a   Conte, PierFranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CEFTRIAXONE; CISPLATIN; CLOBAZAM; CLONIDINE; CORTISONE ACETATE; DACARBAZINE; DESMOPRESSIN; FUROSEMIDE; IPILIMUMAB; PROPRANOLOL; RECOMBINANT INTERFERON; VALPROIC ACID; VINBLASTINE;

ADENOHYPOPHYSIS DISEASE; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTITIS; DIFFUSION WEIGHTED IMAGING; DIURETIC THERAPY; DRUG MEGADOSE; FEMALE; GRAND MAL SEIZURE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MELANOMA; NEPHROSTOMY; POLYURIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; TACHYCARDIA; TONIC CLONIC SEIZURE; URETHRA OBSTRUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; SKIN NEOPLASMS; VAGINAL NEOPLASMS;

EID: 84857517981     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.7886     Document Type: Article

References (25)

1. Hinchey J, Chaves C, Appignani B, et al: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494-500, 1996 (Pubitemid 26067737)
2. Bartynski WS: Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29:1036-1042, 2008
3. Ito Y, Arahata Y, Goto Y, et al: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19:415-417, 1998 (Pubitemid 30422741)
4. Baker WJ, Royer GL Jr, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 9:679-693, 1991
5. Kwon EJ, Kim SW, Kim KK, et al: A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat 41:53-55, 2009
6. Skelton MR, Goldberg RM, O'Neil BH: A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 6:386-388, 2007 (Pubitemid 46340206)
7. de Oliveira RA, Fechine LM, Neto FC, et al: Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. Int Urol Nephrol 40:1095-1098, 2008
8. Wong R, Beguelin GZ, de Lima M, et al: Tacrolimus-associated posterior reversible encephalopathy syndrome after allogenic haematopoietic stem cell transplantation. Br J Haematol 122:128-134, 2003 (Pubitemid 36819347)
9. Irvin W, MacDonald G, Smith JK, et al: Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 25:2484-2486, 2007 (Pubitemid 46999222)
10. Cumurciuc R, Martinez-Almoyna L, Henry C, et al: Posterior reversible encephalopathy syndrome during sunitninb therapy. Rev Neurol 164:605-607, 2008 (Pubitemid 351893095)
11. Tateishi Y, Yasuyuki I, Kazumi K, et al: A case of autoimmune thyroid disease presenting posterior reversible encephalopathy syndrome. J Neurol Sci 271:203-206, 2008
12. Baizabal-Cavallo JF, Barragàn-Campos HM, Padilla-Aranda HJ, et al: Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 111:359-363, 2009
13. Fugate JE, Claassen DO, Cloft HJ, et al: Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Pro 85:427-432, 2010
14. Port JD, Beauchamp NJ Jr: Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics 18:353-367, 1998 (Pubitemid 128466858)
15. Schwartz RB, Jones KM, Kalina P, et al: Hypertensive encephalopathy: Findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159:379-383, 1992
16. Bartynski WS, Boardman JF, Zeigler ZR, et al: Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 27:2179-2190, 2006 (Pubitemid 44788652)
17. Toole JF: Lacunar syndromes and hypertensive encephalopathy, in Toole JF (ed), Cerebrovascular Disorders, 5th ed. New York, NY, Raven, 1999, pp 342-355
18. Zwienenberg-Lee M, Muizelaar JP: Clinical pathophysiology of traumatic brain injury, in Winn HR (ed): Youmans Neurological surgery (ed 5). Philadelphia, PA, Saunders, 200, pp 5039-5064
19. Kofler J, Bartynski WS, Reynolds TQ, et al: Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy. J Comput Assist Tomogr 35:39-42, 2011
20. Edvinsson L, Owman C, Siesjö B: Physiological role of cerebrovascular sympathetic nerves in the autoregulation of cerebral blood flow. Brain Res 117:519-523, 1976
21. Fong L, Small EJ: Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283, 2008
22. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
23. Yang JC, Hughes M, Kammula U: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830, 2007 (Pubitemid 350295361)
24. Chmiel KD, Suan D, Liddle C, et al: Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237-240, 2011
25. Liakou CI, Kamat A, Tang DN, et al: CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105:14987-14992, 2008